Vivus Reports Narrower-Than-Expected Loss (VVUS)

3/8/2010-Vivus (NASDAQ: VVUS) reported a Q4 loss of $0.16 topping consensus estimates for a loss of $0.25.

Sales in the quarter plunged 70% to $8.6 million, but came in ahead of consensus estimates of $6.9 million.

"This past year was transformational for VIVUS given the significant achievements in both the Qnexa and avanafil investigational product programs, which are being developed to address the obesity and erectile dysfunction markets with highly differentiated products that address unmet needs," stated Leland Wilson, chief executive officer of VIVUS. "We look forward to continued clinical and regulatory momentum in 2010 as we continue to work with the FDA during the review of the Qnexa NDA and as we report additional avanafil pivotal data."

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup